

**REMARKS**

***Claim Amendments***

Claims 1 and 4-10 are pending. Claims 1 and 10 are amended. Claims 2, 3 and 11 are canceled without prejudice or disclaimer to the subject matter therein. Applicants reserve the right to file one or more divisional and/or continuations directed to the canceled subject matter. No new matter is added.

***Claim Objections***

Claim 1 is objected to as containing subject matter drawn to a non-elected invention. The Office Action also advises that should 10 be found allowable, claim 11 will be objected to under 37 C.F.R. § 1.75 as being a substantial duplicate thereof.

Applicants have amended claim 1 to remove the reference to imidazotriazinone compounds of formula (IB). Applicants have also canceled claim 11. Accordingly, the claim objections have been rendered moot.

***Claim Rejection under 35 U.S.C. § 112, first paragraph— Enablement***

Claims 1, 2 and 4-11 stand rejected under 35 U.S.C. § 112, first paragraph, because the specification, while being enabling for a compound, composition, or pharmaceutically acceptable salt, allegedly does not reasonably provide enablement for a solvate of the claimed compounds. Furthermore, claim 11 stands rejected as the specification allegedly does not reasonably provide enablement for a PDE 7 inhibitor.

Applicants have amended claims 1 and 10 to delete “or solvates” and canceled claim 11. Accordingly, the enablement rejections have been rendered moot.

**CONCLUSION**

Applicants respectfully submit that claims are in condition for allowance, and such disposition is earnestly solicited. Should the Examiner believe that any issues remain after consideration of this response, the Examiner is invited to contact the Applicants' undersigned representative to discuss and resolve such issues.


This response is being filed within the three-month period of time set forth in the Office Action. Accordingly, no fee is due. However, in the event that any fees are deemed necessary by the USPTO to enter and consider this amendment, or to maintain the instant application pending, please charge such fees to the undersigned's **Deposit Account No. 50-0206**.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: November 5, 2008

By:



Robert M. Schulman  
Registration No. 31,196

Alexander H. Spiegler  
Registration No. 56,625

HUNTON & WILLIAMS LLP  
Intellectual Property Department  
1900 K Street, N.W., Suite 1200  
Washington, DC 20006-1109  
(202) 955-1500 (telephone)  
(202) 778-2201 (facsimile)